Q1 EARNINGS: Boston in line but issues remain; LabCorp reaps Covance rewards
This article was originally published in Clinica
Executive Summary
Boston Scientific’s share price dipped 1% after it reported first quarter results that were “generally in line,” according to Jefferies analyst Raj Denhoy, but trimmed its guidance for 2015. The analyst noted that while the turnaround at the company continues, its shares are fairly valued at $17.75, so he has maintained his ‘hold’ rating.